Gmeiner, Jonas
Bulach, Bernhardt
Lüsebrink, Enzo
Binzenhöfer, Leonhard
Kupka, Danny
Stocker, Thomas
Löw, Kornelia
Weckbach, Ludwig
Rudi, Wolf-Stephan
Petzold, Tobias
Kääb, Stefan
Hausleiter, Jörg
Hagl, Christian
Massberg, Steffen
Orban, Martin
Scherer, Clemens
Clinical trials referenced in this document:
Documents that mention this clinical trial
Comparison of balanced and unbalanced crystalloids as resuscitation fluid in patients treated for cardiogenic shock
https://doi.org/10.1186/s40560-023-00687-y
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 15 June 2023
Accepted: 30 August 2023
First Online: 6 September 2023
Declarations
:
: The study was approved by the local ethics committee of the Ludwig-Maximilians University Munich (IRB number: 18–001).
: Not applicable.
: Martin Orban: Speaker honoraria from Abbott Medical, AstraZeneca, Abiomed, Bayer vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland, Edwards Lifesciences Services, Sedana Medical, support for attending meetings from AstraZeneca, Stocks from Abbott Laboratories, Abbvie, AstraZeneca, Bayer, Biontech, Bristol-Meyer- Squibb, Curevac, Draegerwerk, Fresenius Medical Care, Gilead sciences, Inari Medical, Johnson&Johnson, Linde, Merck US, Moderna, NovoNordisk, Nuance Communications, Pfizer, Proctor&Gamble, Roche, SAP, Siemens healthiniers, Zoom. Jörg Hausleiter: Speaker honoraria from and serves as consultant for Abbott Vascular and Edwards Lifesciences. Clemens Scherer: Speaker honoraria from AstraZeneca. Ludwig Weckbach: Speaker honoraria from AstraZeneca and Bayer. Remaining authors: no conflicts of interest to declare.